oncolyt
viru
immunotherapi
therapeut
approach
cancer
treatment
util
nativ
genet
modifi
virus
select
replic
within
tumour
cell
abil
virus
kill
cancer
cell
recogn
nearli
centuri
past
decad
clinic
trial
document
therapeut
benefit
patient
interest
oncolyt
virus
increas
base
better
understand
viral
biolog
tumour
immunolog
molecular
genet
furthermor
recent
random
phase
iii
clinic
trial
demonstr
improv
durabl
respons
rate
patient
advanc
melanoma
treat
modifi
herp
simplex
viru
type
encod
colonystimul
factor
gmcsf
viru
term
talimogen
laherparepvec
tvec
amgen
wide
anticip
first
oncolyt
viru
immunotherapi
approv
us
food
drug
administr
fda
treatment
cancer
success
tvec
like
promot
drug
develop
within
new
class
cancer
therapeut
nearli
million
vertebr
virus
approxim
thought
infect
mammalian
virus
sever
share
properti
includ
genet
element
compos
singl
doublestrand
dna
rna
abil
infect
host
cell
replic
permiss
condit
tabl
outcom
viral
infect
highli
variabl
depend
pathogen
natur
viral
encod
gene
interact
viru
host
immun
system
abil
viru
replic
andor
induc
latenc
follow
infect
insight
mechan
viral
entri
replic
induct
andor
suppress
immun
respons
lytic
versu
latent
infect
led
intens
interest
util
virus
treatment
human
diseas
use
select
oncolyt
vector
treatment
specif
type
cancer
contrast
standard
viralbas
vaccin
oncolyt
virus
directli
infect
lyse
tumour
cell
situ
necessarili
requir
defin
antigen
includ
vector
tumourassoci
antigen
may
releas
die
tumour
cell
oncolyt
virus
also
provid
addit
danger
signal
promot
effici
antitumour
immun
respons
although
incomplet
understood
oncolyt
virus
thought
mediat
antitumour
activ
two
distinct
mechan
action
select
replic
within
neoplast
cell
result
direct
lytic
effect
tumour
cell
induct
system
antitumour
immun
rel
contribut
mechan
may
differ
depend
natur
type
cancer
cell
characterist
viral
vector
interact
viru
tumour
microenviron
host
immun
system
certain
virus
abil
enter
cancer
cell
select
replic
within
cell
although
oncolyt
virus
enter
normal
cancer
cell
inher
abnorm
cancer
cell
respons
stress
cell
signal
homeostasi
provid
select
advantag
viral
normal
host
cell
antivir
machineri
respons
detect
clearanc
virus
may
also
abnorm
cancer
cell
exampl
protein
kinas
r
pkr
critic
factor
help
clear
intracellular
viral
infect
pkr
may
absent
cancer
cell
allow
increas
viral
replic
wherea
may
activ
cancer
cell
lowgrad
tumour
differ
influenc
therapeut
activ
oncolyt
viru
immun
respons
oncolyt
virus
appear
import
compon
antitumour
effect
doubleedg
sword
one
hand
virus
help
promot
immun
respons
tumour
cell
allow
tumour
antigen
present
context
activ
viral
infect
hand
neutral
antivir
respons
may
block
viru
replic
ongo
infect
tumour
cell
therapeut
outcom
depend
complex
interplay
oppos
forc
system
immun
fulli
engag
howev
therapeut
respons
may
seen
local
inject
tumour
distant
site
uninfect
tumour
growth
mani
virus
propos
vector
oncolyt
viru
immunotherapi
consider
work
done
optim
viral
vector
attenu
pathogen
enhanc
date
adenovirus
poxvirus
coxsackievirus
polioviru
measl
viru
newcastl
diseas
viru
ndv
reoviru
other
enter
earlyphas
clinic
trial
two
virus
tvec
shanghai
sunway
biotech
achiev
regulatori
review
genet
modifi
oncolyt
adenoviru
combin
chemotherapi
approv
treatment
nasopharyng
carcinoma
china
novemb
ref
review
provid
comprehens
overview
critic
issu
develop
oncolyt
viru
immunotherapi
discuss
preclin
clinic
data
support
role
oncolyt
virus
cancer
therapi
detail
uniqu
challeng
oncolyt
virus
drug
develop
oncolyt
virus
live
viral
particl
overal
design
oncolyt
viru
strategi
must
consid
approach
tumour
cell
target
attenu
viral
pathogenesi
well
approach
limit
viral
immunogen
promot
tumour
cell
kill
immunogen
flexibl
recombin
engin
allow
explor
number
strategi
enhanc
effect
oncolyt
virus
target
oncolyt
virus
cancer
cell
mani
oncolyt
virus
current
clinic
natur
tropism
cell
surfac
protein
aberrantli
express
cancer
cell
fig
exampl
use
herpesviru
entri
mediat
hvem
select
nectin
cell
entri
surfac
receptor
overexpress
cancer
cell
includ
melanoma
variou
measl
viru
specif
edmonston
strain
util
surfac
receptor
cell
normal
function
prevent
cell
elimin
inactiv
complement
pathway
immun
system
often
overexpress
cancer
coxsackieviru
enter
cell
via
intercellular
adhes
molecul
also
known
decay
acceler
factor
daf
also
known
overexpress
cancer
multipl
myeloma
melanoma
breast
cancer
although
coxsackievirus
may
also
use
nectin
cell
entri
echoviru
member
enteroviru
famili
increas
specif
ovarian
cancer
cell
use
domain
integrin
cell
entri
overexpress
anoth
member
enteroviru
famili
polioviru
enhanc
specif
variou
cancer
target
receptor
potenti
impair
antitumour
nk
cell
respons
overexpress
cancer
sindbi
viru
member
togavirida
famili
target
cancer
cell
overexpress
kda
laminin
receptor
promot
cancer
cell
invas
oncolyt
virus
also
engin
directli
target
uniqu
cell
surfac
receptor
express
cancer
cell
exampl
includ
adenoviru
modifi
bind
integrin
highli
express
ovarian
cancer
cell
current
investig
clinic
exampl
engin
specif
includ
lentivirus
pseudotyp
modifi
glycoprotein
sindbi
viru
shown
increas
specif
human
melanoma
mous
xenograft
furthermor
measl
viru
engin
express
singlechain
antibodi
recogn
carcinoembryon
antigen
cea
tumour
antigen
select
express
certain
exploit
aberr
signal
pathway
cancer
number
molecular
target
promot
viru
accumul
replic
within
tumour
cell
exampl
tumour
cell
frequent
overexpress
b
cell
lymphoma
bcl
famili
cell
surviv
protein
hallmark
neoplast
transform
ndv
target
cancer
cell
overexpress
bclxl
overexpress
protein
prevent
apoptosi
thu
permit
incub
time
need
viru
multipli
form
syncytia
requir
viral
addit
bcl
famili
ra
signal
pathway
regul
mani
aspect
carcinogenesi
includ
resist
cell
death
fig
reoviru
vaccinia
viru
show
natur
select
cancer
cell
overact
ra
signal
pathway
normal
healthi
cell
reoviru
abl
enter
cell
begin
produc
viral
rna
activ
pkr
pathway
activ
pkr
turn
inhibit
protein
translat
prevent
product
viral
particl
stop
spread
howev
rastransform
cancer
cell
initi
pkr
pathway
render
cancer
cell
permiss
viral
infect
ultim
cell
attenu
oncolyt
viru
viral
gene
encod
uniqu
short
glycoprotein
delet
result
preferenti
lysi
tumour
cell
compar
normal
occur
part
delet
render
unabl
block
pkr
phosphoryl
replic
cell
defect
pkr
vaccinia
viru
member
poxviru
famili
depend
epiderm
growth
factor
receptor
egfr
induc
ra
signal
viral
poxvirus
encod
ligand
trigger
egfr
signal
cancer
cell
overexpress
egfr
therefor
augment
ra
signal
permiss
vaccinia
viru
cancer
cell
often
defect
antivir
mechan
base
type
ifn
signal
provid
virus
replic
advantag
cancer
cell
includ
vaccinia
rabbit
myxoma
vesicular
stomat
viru
vsv
type
ifn
critic
antivir
antitumour
respons
healthi
cell
promot
immun
respons
clear
viru
also
reduc
cellular
prolifer
activ
proapoptot
protein
ref
multipl
type
cancer
inactiv
pathway
either
reduc
express
type
ifn
limit
type
ifn
signal
via
reduc
receptor
express
alter
downstream
signal
fig
thu
oncolyt
virus
increas
specif
cancer
cell
environ
type
ifn
respons
limit
healthi
cell
virus
clear
ifnmedi
respons
oncolyt
virus
also
engin
take
advantag
abnorm
signal
pathway
cancer
cell
insert
promot
activ
cancer
cell
tissuerestrict
exampl
adenoviru
adenovir
protein
inhibit
cell
cycl
place
control
promot
prostatespecif
antigen
psa
current
evalu
patient
prostat
viru
produc
healthi
cell
cell
undergo
apoptosi
therebi
restrict
viral
prolifer
healthi
tissu
howev
prostat
cancer
cell
psa
promot
highli
activ
select
express
result
prolifer
adenoviru
virusmedi
cell
lysi
similar
manner
oncolyt
adenoviru
engin
express
control
human
telomeras
revers
transcriptas
tert
promot
activ
larg
number
furthermor
two
bind
site
transcript
factor
regul
cell
cycl
includ
tert
promot
restrict
prolifer
activ
divid
cell
anoth
exampl
oncolyt
adenoviru
replic
restrict
retinoblastoma
rb
defect
cell
common
mutat
cancer
express
place
regul
healthi
cell
rb
inhibit
thu
inhibit
furthermor
adenovirus
engin
select
replic
hypox
environ
found
insid
tumour
place
gene
transcript
regul
hypoxiainduc
transcript
factor
strategi
shown
effect
murin
xenograft
model
sever
oncolyt
adenovirus
includ
design
delet
gene
code
protein
bind
inactiv
proapoptot
protein
ref
thu
healthi
cell
infect
virus
undergo
mediat
abort
apoptosi
wherea
cancer
cell
commonli
inactiv
remain
suscept
viral
infect
furthermor
adenovirus
preferenti
prolifer
lyse
cancer
cell
account
nearli
cancer
anoth
approach
improv
postentri
tumour
specif
encod
synthet
mirna
target
sequenc
mirt
untransl
region
utr
fusion
gene
measl
viru
sequenc
bind
cellular
microrna
mirna
repress
viral
replic
normal
cancer
cell
exhibit
differenti
express
cognat
mirna
element
engin
oncolyt
viru
mirt
block
replic
normal
cell
specif
mirna
express
construct
design
use
glioma
shown
limit
viral
replic
neuron
constitut
express
high
level
allow
prolifer
glioma
cell
frequent
downregul
ref
attenu
viral
pathogenesi
oncolyt
virus
live
virus
potenti
caus
acut
toxic
case
latent
infect
chronic
diseas
although
oncolyt
activ
may
profound
nativ
virus
potenti
viral
pathogenesi
may
also
high
result
limit
ratio
potenti
pathogen
highli
depend
viru
presenc
natur
engin
attenu
factor
exampl
virul
immuneevas
latencypromot
gene
host
immun
respons
date
seriou
advers
event
report
clinic
trial
followup
patient
often
short
incomplet
clinic
relev
oncolyt
virus
util
attenu
vector
natur
occur
less
virul
variant
particular
virus
prevent
acut
longterm
toxic
exampl
latter
variant
avian
viru
ndv
test
clinic
trial
see
supplementari
inform
tabl
edmonston
strain
measl
viru
commonli
use
prophylact
measl
vaccin
select
clinic
trial
patient
gbm
tabl
exampl
engin
attenu
oncolyt
viru
tvec
known
caus
neurovirul
latent
infect
toxic
mediat
viral
gene
product
counteract
type
ifn
respons
antagon
pkr
signal
pathway
within
nondivid
delet
tvec
mean
abl
grow
within
neuron
mediat
latent
infect
date
report
latent
infect
tvec
attenu
vaccinia
viru
also
attenu
limit
lytic
activ
cancer
cell
nonattenu
vaccinia
viru
infect
viral
protein
term
vaccinia
growth
factor
vgf
secret
act
host
egfr
activ
ra
signal
pathway
activ
promot
cellular
prolifer
lead
increas
product
thymidin
kinas
tk
help
promot
viral
replic
howev
attenu
vaccinia
viru
delet
vgf
make
replic
normal
cell
difficult
allow
viral
prolifer
cell
aberr
signal
frequent
found
cancer
anoth
compon
necessari
infect
healthi
cell
vaccinia
protein
block
type
ifn
attenu
vaccinia
viru
delet
healthi
cell
becom
suscept
type
ifn
antivir
respons
infect
limit
howev
cancer
cell
commonli
disrupt
type
ifn
pathway
evad
immun
system
thu
suscept
infect
subsequ
lysi
furthermor
delet
may
increas
activ
oncolyt
vaccinia
viru
type
ifn
produc
result
vaccinia
infect
tumour
block
contrast
delet
pathogen
viral
gene
express
virul
gene
also
restrict
tumour
tissu
incorpor
promot
regul
express
virul
gene
describ
adenovirus
engin
express
limit
tumour
cell
transcript
regul
tumourspecif
promot
although
revers
nativ
viru
natur
homolog
recombin
remain
theoret
concern
evid
happen
clinic
augment
antitumour
immun
process
tumour
clearanc
immun
stimul
critic
antitumour
activ
oncolyt
virus
sever
strategi
devis
engin
oncolyt
virus
effect
stimul
antitumour
immun
respons
exampl
antitumour
immun
respons
augment
viral
express
proinflammatori
cytokin
andor
cell
costimulatori
molecul
strategi
well
describ
virus
adenoviru
vaccinia
viru
studi
mice
demonstr
reject
contralater
uninject
flank
tumour
gmcsf
cytokin
promot
dendrit
cell
accumul
matur
engin
viral
gmcsf
thought
improv
tumour
antigen
present
stimul
robust
cell
respons
gmcsf
includ
adenovirus
ref
vaccinia
viru
ref
adenoviru
express
heat
shock
protein
cancer
cell
increas
chaperon
protein
proteas
enhanc
protein
degrad
process
use
increas
tumour
antigen
approach
may
also
role
epitop
spread
apc
preferenti
take
peptid
bound
oncolyt
virus
tvec
strategi
also
devis
enhanc
immun
respons
delet
protein
block
function
tap
transport
associ
antigen
process
thu
prevent
infect
cell
present
antigen
cancer
glioblastoma
inher
resist
apoptosi
even
infect
virus
owe
dysregul
apoptot
pathway
oncolyt
parvoviru
howev
shown
kill
glioma
cell
activ
immunogen
cathepsinmedi
death
furthermor
parvoviru
also
induc
immun
respons
gbm
potenti
bystand
effect
involv
increas
inflammatori
cytokin
tumour
antigen
enhanc
lytic
activ
inclus
suicid
gene
gene
render
cell
sensit
apoptosi
therapi
drug
oncolyt
virus
enhanc
abil
directli
kill
cancer
exampl
proapoptot
molecul
tnfrelat
apoptosisinduc
ligand
trail
includ
viral
construct
enhanc
cell
death
trigger
immun
use
tumourenrichedtissuespecif
promot
preferenti
express
suicid
gene
cancer
cell
success
limit
side
effect
improv
therapeut
effect
oncolyt
virus
sever
preclin
model
exampl
adenoviru
adochsvtk
develop
treatment
bone
tumour
encod
gene
tk
driven
osteocalcin
tk
convert
thymidin
analogu
ganciclovir
monophosph
get
incorpor
dna
replic
cell
result
termin
dna
synthesi
ultim
cell
system
express
tk
restrict
cell
activ
osteocalcin
promot
increas
suscept
treatment
thymidin
analogu
ganciclovir
howev
ganciclovir
block
viral
replic
approach
may
inhibit
oncolyt
viru
two
suicid
gene
test
bacteri
cytosin
deaminas
cd
adenoviru
death
protein
adp
cd
transform
cytotox
adp
nuclear
membran
glycoprotein
requir
late
stage
adenoviru
infect
effici
cell
lysi
releas
viral
particl
enhanc
lytic
activ
report
oncolyt
adenoviru
adp
gene
insert
adenovir
locu
result
adp
limit
antivir
immun
respons
although
immun
stimul
critic
antitumour
activ
oncolyt
virus
effect
balanc
potenti
rapid
clearanc
viru
antivir
immun
moreov
human
natur
artifici
vaccin
expos
oncolyt
virus
may
therefor
preexist
neutral
antibodi
cellular
immun
oncolyt
virus
one
strategi
limit
viru
neutral
util
altern
viru
serotyp
multipl
serotyp
exist
adenovirus
vsv
allow
serotyp
switch
inject
prevent
antibodi
neutral
although
measl
viru
natur
switch
serotyp
measl
virus
engin
mimic
serotyp
switch
shown
limit
neutral
antibodi
titr
strategi
overcom
viral
clearanc
includ
pegyl
coval
conjug
polyethylen
glycol
viral
coat
vsv
adenoviru
polym
coat
adenoviru
prevent
antibodi
bind
polym
coat
adenoviru
reduc
target
cover
viral
protein
requir
cell
entri
simultan
increas
circul
time
investig
also
abl
protect
oncolyt
virus
antibodi
use
cell
carrier
mesenchym
stem
cell
infect
ex
vivo
transfer
back
host
traffick
tumour
cell
respons
may
dampen
express
viral
gene
product
block
antigen
present
therebi
limit
detect
cell
prolong
viral
addit
modifi
viru
attempt
made
suppress
host
immun
system
exampl
pretreat
cyclophosphamid
strategi
shown
enhanc
oncolyt
efficaci
hsv
glioma
enhanc
viru
bioavail
addit
strategi
avoid
viral
neutral
describ
number
preclin
studi
investig
method
enhanc
oncolyt
viru
bioavail
exampl
treatment
oncolyt
virus
combin
vasoact
vasonorm
treatment
local
lowdos
improv
viral
deliveri
viral
penetr
also
enhanc
pretreat
tumour
microenviron
proteolyt
enzym
hyaluronidas
collagenas
break
sievelik
barrier
pose
extracellular
matrix
ecm
oncolyt
virus
also
engin
express
ecmdegrad
enzym
hyaluronidas
shown
increas
tumour
dissemin
therapeut
activ
melanoma
xenograft
furthermor
oncolyt
virus
select
andor
engin
overcom
physic
barrier
interstiti
pressur
acid
hypox
environ
present
tumour
spread
cancer
cell
follow
induct
cell
fusion
process
protect
viru
physic
limit
associ
need
extracellular
propag
limit
infect
intracellular
space
exampl
ndv
coronaviru
orthomyxoviru
paramyxoviru
use
fusogen
membran
glycoprotein
fmg
propag
viral
infect
cell
furthermor
vsv
engin
express
ndv
fusogen
mutant
f
sindbi
viru
engin
express
hyperfusogen
envelop
glycoprotein
gibbon
ape
leukaemia
viru
convey
fusogenicbas
viral
measl
viru
engin
activ
fusogen
membran
glycoprotein
f
context
high
level
matrix
metalloproteinas
mmp
present
tumour
rather
normal
regul
uniqu
challeng
develop
oncolyt
virus
new
class
anticanc
drug
includ
need
practic
clinic
trial
design
end
point
respons
assess
criteria
valid
pharmacodynam
pharmacokinet
pkpd
assay
biosafeti
issu
nontradit
regulatori
manufactur
commerci
issu
pharmacodynam
consider
oncolyt
virus
differ
standard
drug
sever
uniqu
way
live
virus
prolifer
upon
clinic
administr
result
variabl
effect
dose
present
littl
data
avail
correl
viral
dose
vivo
replic
potenti
therapeut
respons
investig
relat
viral
replic
clinic
respons
relev
preclin
model
clinic
trial
import
establish
safe
effect
dose
guidelin
oncolyt
virus
remov
result
cell
metabol
bind
circul
protein
rather
subject
host
antivir
immun
respons
multipl
factor
need
consid
regard
includ
preexist
neutral
antibodi
titr
virusspecif
memori
cell
respons
potenti
disabl
virus
haemagglutinin
bind
innat
abil
viru
evad
immun
detect
addit
mani
tumour
microenviron
highli
immunesuppress
limit
host
immun
respons
studi
evalu
preexist
antivir
immun
induct
posttreat
immun
respons
viral
vector
tumourassoci
antigen
import
better
understand
dynam
oncolyt
virus
clear
control
patient
cancer
biosafeti
consider
oncolyt
virus
thu
far
associ
rel
toler
safeti
profil
numer
clinic
trial
conduct
across
wide
rang
cancer
nonetheless
replic
potenti
agent
requir
attent
infect
control
issu
includ
procedur
safe
storag
prepar
handl
administr
viru
true
potenti
infect
depend
natur
viru
comorbid
condit
within
patient
close
household
contact
healthcar
worker
may
expos
viru
addit
mani
oncolyt
virus
contain
recombin
dna
element
potenti
impact
gene
segment
potenti
recombin
wildtyp
virus
environ
theoret
concern
although
univers
accept
standard
respect
biosafeti
oncolyt
virus
development
plan
includ
polici
safe
handl
storag
agent
guidelin
healthcar
worker
especi
pharmacist
prepar
agent
physician
nurs
administ
agent
establish
agent
safe
manag
standard
univers
precaut
addit
educ
materi
need
develop
viru
clear
instruct
deal
accident
spill
clean
treatment
room
patient
visit
instruct
possibl
antidot
event
accident
exposur
case
warn
issu
patient
healthcar
worker
avoid
contact
agent
exampl
immunocompromis
individu
pregnant
women
expos
vaccinia
viru
plan
manag
viru
administr
site
also
clearli
delin
patient
healthcar
worker
event
possibl
contamin
bandag
dress
plan
proper
dispos
healthcar
set
home
develop
oncolyt
virus
new
agent
potenti
dissemin
mani
plan
may
need
consid
expand
surveil
programm
present
clear
regulatori
agenc
manag
biosafeti
issu
consider
postmarket
risk
evalu
mitig
strategi
rem
process
may
indic
despit
theoret
concern
note
report
household
transmiss
oncolyt
virus
literatur
date
also
import
note
mani
oncolyt
virus
attenu
nativ
strain
often
ubiquit
environ
howev
isol
case
exposur
healthcar
profession
handl
oncolyt
virus
laboratori
patient
administr
case
gener
without
signific
sequela
although
individu
requir
treatment
antivir
agent
clinic
trial
design
respons
assess
recent
evid
suggest
kinet
immunemedi
respons
may
much
slower
compar
therapeut
agent
directli
kill
tumour
cell
activ
immun
system
result
indirect
method
tumour
cell
kill
requir
prime
expans
immun
effector
cell
notabl
cytotox
cell
time
cell
undergo
homeostat
expans
traffick
site
tumour
growth
lytic
destruct
cancer
cell
inflammatori
clearanc
necrot
tumour
fig
may
result
term
pseudoprogress
clinic
trial
must
consid
nontradit
end
point
account
emerg
delay
therapeut
pseudoprogress
may
complic
interpret
clinic
result
consid
futur
oncolyt
viru
trial
addit
oncolyt
virus
repres
challeng
respect
subject
elig
dose
biodistribut
assess
design
clinic
trial
mani
clinic
studi
util
local
deliveri
viru
patient
tumour
must
access
inject
date
viru
dose
typic
base
maximum
concentr
viru
possibl
current
purif
techniqu
volum
tumour
determin
viru
administr
quit
cumbersom
studi
adequ
explor
associ
viru
dose
therapeut
respons
occurr
advers
nonetheless
oncolyt
virus
replic
within
tumour
tissu
even
small
dose
may
result
signific
clinic
activ
provid
viru
rapidli
clear
immun
system
observ
clinic
trial
oncolyt
polioviru
final
individu
assay
assess
viru
distribut
need
evalu
pharmacodynam
viru
deliveri
ideal
includ
data
presenc
viru
within
target
cell
exampl
cancer
cell
lack
viral
replic
nontarget
cell
viru
shed
within
bodi
fluid
evid
latent
infect
viral
clearanc
virusspecif
tumourspecif
humor
cellular
immun
respons
although
mani
trial
made
progress
establish
assay
standard
agreement
within
field
valid
correl
end
point
sever
strategi
clinic
assess
oncolyt
virus
vivo
develop
common
method
determin
tissu
uptak
use
express
fluoresc
dye
green
fluoresc
protein
gfp
luciferas
viral
vector
quantit
viral
transcript
within
infect
techniqu
howev
challeng
patient
requir
inclus
foreign
transgen
unknown
clinic
consequ
potenti
immun
recognit
difficulti
imag
fluoresc
activ
deep
tissu
layer
contrast
measl
viru
engin
express
protein
enzym
reli
fluoresc
vivo
monitor
measl
viru
engin
encod
solubl
extracellular
domain
human
cea
upstream
nucleoprotein
gene
allow
quantit
monitor
viral
gene
express
serial
peripher
blood
measur
cea
anoth
interest
strategi
util
measl
viru
express
human
thyroid
sodium
iodid
symport
ni
ni
concentr
radioact
iodin
monitor
use
singl
photon
emiss
comput
tomographi
spect
positron
emiss
tomographi
pet
imag
encod
viral
tk
mutat
dopamin
receptor
use
trap
radioact
tracer
monitor
viru
locat
replic
system
viral
tk
phosphoryl
inject
radioact
fiau
trap
radioact
signal
within
mutat
dopamin
receptor
act
similar
fashion
trap
radioact
tracer
monitor
use
pet
imag
addit
imag
tumour
biopsi
procedur
perform
access
appropri
determin
viral
titr
target
nontarget
tissu
tumour
biopsi
sampl
provid
function
data
well
inform
kinet
propag
oncolyt
viru
collect
bodi
tissu
includ
blood
saliva
urin
may
also
provid
indic
viral
replic
critic
ensur
safeti
determin
bioshed
dynam
therapeut
oncolyt
virus
regulatori
commerci
issu
live
replic
natur
oncolyt
virus
pose
uniqu
regulatori
manufactur
issu
virus
propag
tissu
cultur
requir
method
hightitr
viru
product
test
adventiti
pathogen
assess
viru
puriti
replic
potenti
thu
procedur
laboratori
safeti
manufactur
vial
product
valid
puriti
qualiti
design
result
gener
biolog
cell
cultur
must
consid
virus
difficult
gener
high
titr
lysat
requir
clinic
dose
challeng
biotechnolog
manufactur
aspect
review
extens
viral
vaccin
provid
templat
manufactur
regul
oncolyt
virus
fda
publish
draft
guidanc
document
titl
guidanc
industri
design
analysi
shed
studi
viru
bacteriabas
gene
therapi
oncolyt
product
relev
document
includ
european
director
qualiti
medicin
includ
cell
substrat
product
vaccin
human
use
ref
test
extran
agent
viral
vaccin
human
use
ref
provid
guidelin
qualiti
control
test
materi
cell
use
gener
oncolyt
virus
furthermor
intermedi
viral
batch
need
test
contamin
efficaci
howev
remov
contamin
especi
microbi
viral
contamin
prove
difficult
oncolyt
virus
recombin
protein
method
use
remov
contamin
may
also
target
oncolyt
viru
qualiti
oncolyt
viru
prepar
test
control
cell
standard
readout
combin
virusspecif
neutral
antibodi
confirm
effect
mediat
viru
approach
adapt
method
use
test
human
viral
vaccin
infrastructur
provid
addit
framework
need
widespread
commerci
oncolyt
virus
cancer
therapi
demonstr
signific
improv
durabl
respons
patient
melanoma
treat
tvec
revolution
field
anticanc
therapi
oncolyt
virus
howev
develop
oncolyt
virus
therapeut
agent
requir
care
attent
establish
appropri
clinic
trial
design
dose
regimen
pharmacodynam
assay
educ
programm
address
biosafeti
concern
well
new
manufactur
regulatori
pathway
likewis
care
attent
patient
select
also
import
consider
exampl
immunocompromis
patient
may
good
candid
oncolyt
virusmedi
antitumour
immun
could
compromis
patient
nevertheless
oncolyt
virus
associ
favour
ratio
continu
develop
new
class
drug
anticip
particular
interest
combin
approach
oncolyt
viru
immunotherapi
highli
promis
approach
introduc
new
class
drug
treat
patient
cancer
